BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...we didn’t have at Clarus.” Nick Galakatos, Blackstone Life Sciences The same is true for FerGene Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...Eckhardt is SVP and head of Leaps by Bayer. Dewpoint is developing biomolecular condensate-based therapeutics. FerGene Inc....
...interim basis. Eck was CMO of Immatics Biotechnologies GmbH. Robin Sawka, BioCentury Staff Novavax Inc. Ziopharm Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum...
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

...Ipsen CFO Aymeric Le Chatelier since the departure of David Meek at YE19 to lead FerGene Inc....
Items per page:
1 - 3 of 3
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...we didn’t have at Clarus.” Nick Galakatos, Blackstone Life Sciences The same is true for FerGene Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...Eckhardt is SVP and head of Leaps by Bayer. Dewpoint is developing biomolecular condensate-based therapeutics. FerGene Inc....
...interim basis. Eck was CMO of Immatics Biotechnologies GmbH. Robin Sawka, BioCentury Staff Novavax Inc. Ziopharm Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum...
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

...Ipsen CFO Aymeric Le Chatelier since the departure of David Meek at YE19 to lead FerGene Inc....
Items per page:
1 - 3 of 3